menu
    • menu
    [{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Juvena Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Mubadala Capital"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juvena Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juvena Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juvena Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Undisclosed","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juvena Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Juvena Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Juvena Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Juvena Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery Platform","graph3":"Juvena Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Juvena Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Juvena Therapeutics \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Juvena Therapeutics

    Menu

    Juvena Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $650.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs

                            Details : SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface has initiated a single-arm Phase 2 study evaluating SRF388 in combination with pembrolizumab in patients with NSCLC.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 11, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $650.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $650.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eli Lilly Works Out $650M Juvena Pact to Find Muscle-Boosting Drugs

                            Details : The collaboration aims to discover, develop, and commercialize drug candidates that improve muscle health and body composition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 11, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $650.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161

                            Details : JUV-161 is a muscle regenerating endocrine therapy being investigated for the treatment of Myotonic Dystrophy Type 1 (DM1) and Sarcopenia

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 19, 2025

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-In-Human Study to Evaluate Single Ascending Doses of JUV-161 in Healthy Adult Volunteers

                            Details : JUV-161 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Juvena Receives FDA Orphan Drug Designation for JUV-161 in Myotonic Dystrophy

                            Details : JUV-161, identified via Juvena’s AI platform, restores muscle fiber formation, counters muscle atrophy, and enhances strength, currently in preclinical studies for DM1.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 23, 2024

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Mubadala Capital

                            Deal Size : $41.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic a...

                            Details : JUV-161 is the only protein-based therapeutic being developed for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1).

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            November 08, 2022

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Mubadala Capital

                            Deal Size : $41.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Juvena Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $3.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Juvena Therapeutics Awarded Highly Competitive CIRM Grant To Advance Lead Program, JUV-161, To Treat Myotonic ...

                            Details : The grant will fund the advancement of Juvena's lead program, fusion protein therapeutic JUV-161, for the treatment of the rare muscle-wasting disease, DM1, through initial IND-enabling studies and a pre-IND FDA meeting in the next 12-16 months.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 02, 2022

                            Lead Product(s) : JUV-161

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $3.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth